There are approximately eleven active Reglan lawsuits filed and pending throughout the country. These lawsuits all allege that the manufacturers of Reglan failed to adequately investigate and study the drug, or warn about the potential side effects associated with its use. Plaintiffs in these cases sought to consolidate their claims through Multidistrict Litigation in order to coordinate pre-trial proceedings, eliminate duplicative discovery, and avoid conflicting rulings, but following a hearing held in May 2009, the MDL panel issued an order denying their request. The panel stated in its ruling:
Metoclopramide litigation has a lengthy history, and record indicates that a significant amount of the common discovery has already taken place.
This denial by the MDL panel means that any future Reglan/Metoclopramide lawsuits will proceed as individual suits and will not be formally coordinated. Reglan, or its generic version, Metoclopramide, is a drug approved for the short-term treatment of gastrointestinal disorders like gastroparesis, gastroesophageal reflux, and delayed gastric emptying. Use of this drug for longer than three months has been linked to Tardive Dyskinesia, a neurological disorder that causes repetitive and involuntary movements of the face, torso and limbs. Currently, there is no effective treatment for Tardive Dyskinesia. For more information, please contact Danielle Mason or Chad Cook, who are lawyers in our firm working on Reglan cases, at 800-898-2034 or by email at Danielle.Mason@beasleyallen.com or Chad.Cook@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.